COVID-19: BioNTech expects vaccine trial results for Babies

BioNTech expects results for trial testing of COVID-19 vaccine by September, of which it and Pfizer have developed in babies as young as six months old.

BioNTech Chief Executive, Ugur Sahin said, “In July, the first results could be available for the five to 12 year olds, in September for the younger children.

“If all goes well, as soon as the data is evaluated, we will be able to submit the application for approval of the vaccine for all children in the respective age group in different countries,” he said.

BioNTech and Pfizer asked U.S. regulators this month to approve emergency use of their vaccine for adolescents aged 12 to 15.

A trial published at the end of March found the companies’ COVID-19 vaccine was safe, effective and produces robust antibody responses in adolescents.

The Pfizer/BioNTech two-shot vaccine is already authorized for use in those aged 16 and above.

READ ALSO: Hong Kong to resume Covid-19 vaccinations with BioNTech shots

Kamila/Reuters